GSK dismisses 110 employees in Chinese bribery scandal
UK pharma major GlaxoSmithKline (LSE: GSK) has reportedly sacked more than 100 employees in China due to misconduct over 18 months ago, according to Bloomberg.
The dismissals came as a result of the internal investigation into the corruption scandal for which GSK was fined $480 million last year for bribing doctors to prescribe its products. China is not the only territory in which GSK has been subject to allegations of bribery: the company is investigating its Syrian operations, and has previously investigated such claims in Iraq, Jordan, Lebanon and Poland. The number of whistleblower allegations against staff in China rose to 652 in 2014 from 48 the year before, according to GSK’s annual report published last week.
The company said it is working to improve the integrity of Chinese operations by increasing the monitoring of expense claims, strengthening compliance and hiring external investigators.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze